{"id":183,"date":"2011-02-08T09:39:34","date_gmt":"2011-02-08T14:39:34","guid":{"rendered":"https:\/\/www.bu.edu\/nf-kb\/?page_id=183"},"modified":"2011-04-04T13:35:34","modified_gmt":"2011-04-04T17:35:34","slug":"diseases","status":"publish","type":"page","link":"https:\/\/www.bu.edu\/nf-kb\/physiological-mediators\/diseases\/","title":{"rendered":"Diseases"},"content":{"rendered":"

NF-kB DISEASES<\/span><\/strong><\/p>\n

On this page are listed several diseases in which activation of NF-kB has been implicated.\u00a0 For general reviews on the role of NF-kB in disease, see Aradhya<\/span><\/a> & Nelson (2001), Kumar<\/span><\/a> et al (2004), Yamamoto<\/span><\/a> & Gaynor (2002) or Baldwin<\/span><\/a> (2001).\u00a0 For specific diseases see the listed references, which can be found either on this site (under References) or at PubMed (through the linked references).<\/p>\n

Table 1: General Diseases<\/strong><\/p>\n

Disease<\/strong> Review\/Paper<\/strong><\/p>\n

Ageing\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Chung<\/span><\/a> et al, 2002; Adler<\/span><\/a> et al, 2007; Csizar<\/span><\/a> et al, 2008<\/p>\n

Allergies\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Cousins<\/span><\/a> et al, 2008<\/p>\n

Headaches\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Reuter<\/span><\/a> et al, 2003<\/p>\n

Pain\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Tegeder<\/span><\/a> et al, 2004; Niederberger<\/span><\/a> & Geisslinger, 2008<\/p>\n

Complex Regional Pain Syndrome\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Hettne<\/span><\/a> et al, 2007<\/p>\n

Cardiac Hypertrophy\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Purcell<\/span><\/a> & Molkentin, 2003; Freund<\/span><\/a> et al, 2005; Sen<\/span><\/a> & Roy, 2005<\/p>\n

Muscular Dystrophy (type 2A)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Baghdiguian<\/span><\/a> et al, 1999<\/p>\n

Muscle wasting\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Hasselgren<\/span><\/a>, 2007<\/p>\n

Catabolic disorders\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Holmes-McNary<\/span><\/a>, 2002<\/p>\n

Diabetes mellitus, Type 1\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Ho<\/span><\/a> & Bray, 1999; Eldor<\/span><\/a> et al, 2006<\/p>\n

Diabetes\u00a0 mellitus, Type 2\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Yuan<\/span><\/a> et al, 2001; Lehrke<\/span><\/a> et al, 2004; Chen<\/span><\/a>, 2005<\/p>\n

Obesity\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Gil<\/a> et al, 2007<\/p>\n

Fetal Growth Retardation\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Mammon<\/span><\/a> et al, 2005<\/p>\n

Hypercholesterolemia\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Wilson<\/span><\/a> et al, 2000<\/p>\n

Atherosclerosis\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Ross<\/span><\/a> et al, 2001 ; Li<\/span> & Gao<\/a>, 2005<\/p>\n

Heart Disease\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Valen<\/span><\/a> et al, 2001<\/p>\n

Chronic Heart Failure\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Frantz<\/span><\/a> et al, 2003; Gong<\/span><\/a> et al, 2007<\/p>\n

Ischemia\/reperfusion\u00a0 Toledo-Pereyra<\/span><\/a> et al, 2004; Nichols<\/span><\/a>, 2004; Ridder<\/span> & Schwaninger<\/a>, 2008<\/p>\n

Stroke\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Herrmann<\/span><\/a> et al, 2005<\/p>\n

Cerebral aneurysm\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Aoki<\/span><\/a> et al, 2007; 2009<\/span><\/a><\/p>\n

Angina Pectoris \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Ritchie<\/span><\/a>, 1998<\/p>\n

Pulmonary Disease\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Christman<\/span><\/a> et al, 2000<\/p>\n

Cystic Fibrosis\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Pollard<\/span><\/a> et al, 2005; Carrabino<\/span><\/a> et al, 2006; Rottner<\/span><\/a> et al, 2007<\/p>\n

Acid-induced Lung Injury\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Madjdpour<\/span><\/a> et al, 2003<\/p>\n

Pulmonary hypertension\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Sawada<\/span><\/a> et al, 2007<\/p>\n

Chronic Obstructive Pulmonary<\/p>\n

Disease (COPD)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Barnes<\/span><\/a>, 2002 ; Rahman<\/span><\/a> & Kilty, 2006<\/p>\n

Hyaline Membrane Disease\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Cheah<\/span><\/a> et al, 2005<\/p>\n

Kidney Disease\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Guijarro<\/span><\/a> & Egido, 2001; Camici<\/span><\/a>, 2006; Guzik<\/span><\/a> & Harrison, 2007<\/p>\n

Glomerular Disease\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Zheng<\/span><\/a> et al, 2005<\/p>\n

Alcoholic Liver Disease\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Zima<\/span><\/a> & Kalousova, 2005<\/p>\n

Leptospirosis renal disease\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Yang<\/span><\/a> et al, 2001<\/p>\n

Gut Diseases\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Neurath<\/span><\/a> et al, 1998<\/p>\n

Peritoneal endometriosis\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Gonzalez-Ramos<\/span><\/a> et al, 2007<\/p>\n

Skin Diseaes\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Bell<\/span><\/a> et al, 2003<\/p>\n

Nasal sinusitis\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Xu<\/span><\/a> et al, 2006<\/p>\n

Anhidrotic Ecodermal Dysplasia-ID\u00a0\u00a0\u00a0\u00a0 Puel<\/span><\/a> et al, 2005<\/p>\n

Behcet’s Disease\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Todaro<\/span><\/a> et al, 2005<\/p>\n

Incontinentia pigmenti\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Courtois<\/span> & Israel<\/a>, 2000<\/p>\n

Tuberculosis\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Zea<\/span><\/a> et al, 2006<\/p>\n

Asthma\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Pahl<\/span> & Szelenyi<\/a>, 2002<\/p>\n

Arthritis\u00a0\u00a0\u00a0Roshak<\/span><\/a> et al, 2002 ; Roman-Blas<\/span> & Jimenez<\/a>, 2006; Aud<\/span> & Peng<\/a>, 2006; Okamoto<\/span><\/a>, 2006<\/p>\n

Crohn’s\u00a0 Disease\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Pena<\/span> & Penate<\/a>, 2002<\/p>\n

Colitis (rat)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Chen<\/span><\/a> et al, 2005<\/p>\n

Ocular Allergy\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Bielory<\/span><\/a> et al, 2002<\/p>\n

Glaucoma\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Zhou<\/span><\/a> et al, 2005<\/p>\n

Appendicitis\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Pennington<\/span><\/a> et al, 2000<\/p>\n

Paget’s Disease\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Lin<\/span><\/a> et al, 2007<\/p>\n

Pancreatitis\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Weber<\/span> & Adler<\/a>, 2001 ; Gray<\/span><\/a> et al, 2006<\/p>\n

Periodonitis\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Nichols<\/span><\/a> et al, 2001; Ambili<\/span><\/a> et al, 2005<\/p>\n

Endometriosis\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Guo<\/span><\/a>, 2006; Celik<\/span><\/a> et al, 2008<\/p>\n

Inflammatory Bowel Disease\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Dijkstra<\/span><\/a> et al, 2002; Atreya<\/span><\/a> et al, 2008<\/p>\n

Inflammatory Lung Disease\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Park<\/span> & Christman<\/a>, 2006<\/p>\n

Sepsis\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Wratten<\/span><\/a> et al, 2001; Abraham<\/span><\/a>, 2003<\/p>\n

Silica-induced\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Chen<\/span> & Shi<\/a>, 2002<\/p>\n

Sleep apnoea\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Lavie<\/span><\/a>, 2003<\/p>\n

AIDS (HIV-1)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Hiscott<\/span><\/a> et al., 2001<\/p>\n

Autoimmunity\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Hayashi<\/span> & Faustman<\/a>, 2000; Bacher<\/span> & Schmitz<\/a>, 2004<\/p>\n

Antiphospholipid Syndrome\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Lopez-Pedrera<\/span><\/a> et al, 2005<\/p>\n

Lupus\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Kammer<\/span> & Tsokos<\/a>, 2002 ; Okamoto<\/span><\/a>, 2006; Oikonomidou<\/span><\/a> et al, 2007<\/p>\n

Lupus nephritis\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Zheng<\/span><\/a> et al, 2006, 2008<\/span><\/a><\/p>\n

Chronic Disease Syndrome\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Maes<\/span><\/a> et al, 2007<\/p>\n

Familial Mediterranean Fever\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Onen<\/span><\/a>, 2005<\/p>\n

Hereditary Periodic Fever Syndrome\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Jeru<\/span><\/a> et al, 2008<\/p>\n

Psychosocial stress diseases\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Bierhaus<\/span><\/a> et al, 2004<\/p>\n

Neuropathological Diseases\u00a0Cechetto<\/span><\/a>, 2001; Mattson<\/span> & Camandola<\/a>, 2001;\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Pizzi<\/span> & Spano<\/a>, 2006<\/p>\n

Familial amyloidotic polyneuropathy, inflamm neuropathy Mazzeo<\/span><\/a> et al, 2004<\/p>\n

Traumatic brain injury\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Hang<\/span><\/a> et al, 2005<\/p>\n

Spinal cord injury\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Brambilla<\/span><\/a> et al, 2005<\/p>\n

Parkinson Disease\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Soos<\/span><\/a> et al, 2004, Mogi<\/span><\/a> et al, 2006<\/p>\n

Multiple Sclerosis\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Satoh<\/span><\/a> et al, 2007<\/p>\n

Rheumatic Disease\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Okamoto<\/a>, 2006; Greetham<\/span><\/a> et al, 2007<\/p>\n

Alzheimers\u00a0 Disease\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Mattson<\/span> & Camandola<\/a>, 2001; Collister<\/span> & Albensi<\/a>, 2005<\/p>\n

Amyotropic lateral sclerosis\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Xu<\/span><\/a> et al, 2006<\/p>\n

Huntington’s Disease\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Khoshnan<\/span><\/a> et al, 2004<\/p>\n

Retinal Disease\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Kitaoka<\/span><\/a> et al, 2004<\/p>\n

Cataracts\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Yang<\/span><\/a> et al, 2006<\/p>\n

Hearing loss\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Merchant<\/span><\/a> et al, 2005; Lang<\/span><\/a> et al, 2006<\/p>\n

Cancer\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Gilmore<\/span><\/a> et al, 2002; Karin<\/span><\/a> et al, 2002: Lee<\/span><\/a> et al, 2007 (see\u00a0Table 2, below)<\/p>\n

______________________________________________________________________<\/p>\n

.<\/p>\n

Table 2:\u00a0 Constitutive activation of NF-kB in human cancer cells<\/strong><\/p>\n

Cancer type<\/em><\/strong> Reference<\/strong><\/em><\/p>\n

A: Primary tumors and tumor cell lines<\/strong><\/p>\n

Solid tumors (generally)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Pacifico<\/span><\/a> & Leonardi, 2006<\/p>\n

Breast\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Nakshatri<\/span><\/a> et al, 1997; Sovak<\/span><\/a> et al, 1997; Ahmed<\/span><\/a> et al, 2006<\/p>\n

Cervix\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Nair<\/span><\/a> et al, 2003; Kumar<\/span><\/a> et al, 2005; Shehata<\/span><\/a>, 2005; Ramdass<\/span><\/a> et al, 2006<\/p>\n

Ovary\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Dejardin<\/span><\/a> et al, 1999; Huang<\/span><\/a> et al, 2000<\/p>\n

Vulva\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Seppanen<\/span><\/a> & Vihko, 2000<\/p>\n

Prostate\u00a0\u00a0\u00a0Huang<\/span><\/a> et al, 2001; Palayoor<\/span><\/a> et al, 1999; Fradet<\/span><\/a> et al, 2004; Lessard<\/span><\/a> et al, 2006;\u00a0 Paule<\/span><\/a> et al, 2007<\/p>\n

Kidney\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Oya<\/span><\/a> et al, 2001, 2003<\/span><\/a><\/p>\n

Bladder\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0Horiguchi<\/span><\/a> et al, 2003; Kadhim<\/span><\/a> et al, 2006; Levidou<\/span><\/a> et al, 2008<\/p>\n

Lung\u00a0\u00a0\u00a0\u00a0Tichelaar<\/span><\/a> et al, 2004; Tang<\/span><\/a> et al, 2006; Zhang<\/span><\/a> et al, 2007; Motadi<\/span><\/a> et al, 2007; Stathopoulos<\/a><\/span> et al, 2008<\/p>\n

Mesothelioma\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Bertino<\/span><\/a> et al, 2007; Carbone<\/span><\/a> & Bedrossian, 2006<\/p>\n

Non small-cell lung\u00a0\u00a0\u00a0\u00a0\u00a0Zhang<\/span><\/a> et al, 2006; Tew<\/span><\/a> et al, 2007; Jin<\/span><\/a> et al, 2008<\/p>\n

Liver\u00a0\u00a0\u00a0\u00a0\u00a0Tai<\/span><\/a> et al, 2000, Arsura<\/span><\/a> & Cavin, 2005; Qiao<\/a><\/span> et al, 2006; Seki<\/span><\/a> & Brenner, 2007<\/p>\n

Pancreas\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Wang<\/span><\/a> et al, 1999; Sclabas<\/span><\/a> et al, 2003; Xiong<\/span><\/a>, 2004; Jackson<\/span><\/a> & Evers, 2006;<\/p>\n

Zhang<\/span><\/a> & Rigas, 2006; Sarkar<\/span><\/a> et al, 2006; Weichert<\/span><\/a> et al, 2007; Sebens<\/span><\/a> et al, 2008; Holcomb<\/span><\/a> et al, 2008<\/p>\n

Esophageal\/gastric\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Sutter<\/span><\/a> et al, 2004; Lee<\/span><\/a> et al, 2005; Abdel-Latif<\/span><\/a> et al, 2005, 2008<\/span><\/a>;<\/p>\n

Jackson<\/span><\/a> & Evers, 2006: Levidou<\/span><\/a> et al, 2007<\/p>\n

Laryngeal\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Zhu<\/span><\/a> et al, 2004; Pan<\/span><\/a> et al, 2005<\/p>\n

Stomach\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Sasaki<\/span><\/a> et al, 2001; Wu<\/span><\/a> et al, 2007<\/p>\n

Colon\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Lind<\/span><\/a> et al, 2001; Schottelius<\/span><\/a> & Dinter, 2006; Aranha<\/span><\/a> et al, 2007<\/p>\n

Thyroid\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Visconti<\/span><\/a> et al, 1997; Pacifico<\/span><\/a> et al, 2004; Gombos<\/span><\/a> et al, 2007<\/p>\n

Parathyroid\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Corbetta<\/span><\/a> et al, 2004<\/p>\n

Melanoma\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Yang<\/span><\/a> & Richmond, 2001; Torabian<\/span><\/a> & Kashani-Sabet, 2005;<\/p>\n

Amiri<\/span><\/a> & Richmond, 2005; Ueda<\/span><\/a> & Richmond, 2006; Van den Oord<\/span><\/a> et al, 2007<\/p>\n

Squamous cell carcinoma\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Loercher<\/span><\/a> et al, 2004; Kobielak<\/span><\/a> & Fuchs, 2006<\/p>\n

Head and neck\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Ondrey<\/span><\/a> et al, 1999; Chung<\/span><\/a> et al, 2006; Allen<\/span><\/a> et al, 2007;<\/p>\n

Jackson-Bernitsas<\/span><\/a> et al, 2007<\/p>\n

Endometrial (Uteris)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Pallares<\/a><\/span> et al, 2004; Domenyuk<\/span><\/a> et al, 2007<\/p>\n

Cylindromatosis Kovalenko<\/span><\/a> et al, 2003; Brummelkamp<\/span><\/a> et al, 2003;\u00a0Trompouki<\/span><\/a> et al, 2003<\/p>\n

Brooke-Spiegler, Trichoepithelioma\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Almeida<\/span><\/a> et al, 2007<\/p>\n

Hilar Cholangiocarcinoma\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Chen<\/span><\/a> et al, 2005<\/p>\n

Oral carcinoma\u00a0\u00a0Nakayama<\/span><\/a> et al, 2001; Bindhu<\/span><\/a> et al, 2006; Mishra<\/span><\/a> et al, 2006; Sawhney<\/span><\/a> et al, 2007<\/p>\n

Min<\/span><\/a> et al, 2007<\/p>\n

Astrocytoma\/glioblastoma\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Hayahsi<\/span><\/a> et al, 2001; Garkavtsev<\/span><\/a> et al, 2004<\/p>\n

Neuroblastoma\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Bian<\/span><\/a> et al, 2002; Brown<\/span><\/a> et al, 2007; Widera<\/span><\/a> et al, 2007<\/p>\n

Glioblastoma\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Raychaudhuri<\/a><\/span> et al, 2007; Smith<\/span><\/a> et al, 2007<\/p>\n

Hodgkin\u2019s lymphoma\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Bargou<\/span><\/a> et al, 1996, 1997<\/span><\/a>; Staudt<\/span><\/a>, 2000<\/p>\n

Acute lymphoblastic leukemia\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Kordes<\/span><\/a> et al, 2000; Munzert<\/span><\/a> et al, 2004<\/p>\n

Acute myelogenous leukemia\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Guzman<\/span><\/a> et al, 2001; Fabre<\/span><\/a> et al, 2007<\/p>\n

Acute T-cell leukemia (+\/-HTLV-1)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Arima<\/span><\/a> & Tei, 2001; Horie<\/span><\/a> et al, 2006<\/p>\n

Acute Non-lymphocytic leukemia\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Lei<\/span><\/a> & Zhao, 2007<\/p>\n

Chronic lymphocytic leukemia\u00a0\u00a0Furman<\/span><\/a> et al, 2000 ; Pickering<\/span><\/a> et al, 2006; Herwamana<\/span><\/a> et al, 2008<\/p>\n

Burkitts Lymphoma (EBV)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Knecht<\/span><\/a> et al, 2001<\/p>\n

Mantle cell lymphoma\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Martinez<\/span><\/a> et al, 2003<\/p>\n

Myelodysplastic syndrome\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Fabre<\/span><\/a> et al, 2007<\/p>\n

Multiple myeloma\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Berenson<\/span><\/a> et al, 2001; Gilmore<\/span><\/a>, 2007<\/p>\n

Diffuse large B-cell lymphoma\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Davis<\/span><\/a> et al, 2001; Shaffer<\/span><\/a> et al, 2002<\/p>\n

MALT lymphoma \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Sagaert<\/span><\/a> al, 2007; Inagaki<\/span><\/a>, 2007; Du<\/span><\/a>, 2007<\/p>\n

Waldenstrom macroglobulinemia\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Leleu<\/span><\/a> et al, 2008<\/p>\n

B: In vitro transformation of cells<\/strong><\/p>\n

AP12\/MALT1\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Stoffel<\/span><\/a> et al, 2004; Ho<\/span><\/a> et al, 2005; Lucas<\/span><\/a> et al, 2007<\/p>\n

BCR-ABL\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Reuther<\/span><\/a> et al, 1999<\/p>\n

BRAF\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Liu<\/span><\/a> et al, 2007<\/p>\n

DBL\/DBS\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Whitehead<\/span><\/a> et al, 1999<\/p>\n

Muc1\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Ahmad<\/span><\/a> et al, 2007<\/p>\n

Notch1\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Vilimas<\/span><\/a> et al, 2006<\/p>\n

Pim-2\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Fox<\/span><\/a> et al, 2003; Hammerman<\/span><\/a> et al, 2004<\/p>\n

PDGF-beta chain\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Shimamura<\/span><\/a> et al, 2002<\/p>\n

RAF\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Baumann<\/span><\/a> et al, 2000<\/p>\n

RAS\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Finco<\/span><\/a> et al, 1997<\/p>\n

RET\/PTC3\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Russell<\/span><\/a> et al, 2003<\/p>\n

TEL-JAK2\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Santos<\/span><\/a> et al, 2001<\/p>\n

TEL-PDGFR\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0Besancon<\/span><\/a> et al, 1998<\/p>\n

Tio (herpesvirus)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Heinemann<\/span><\/a> et al, 2006<\/p>\n

Vav\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0Palmby<\/span><\/a> et al, 2004<\/p>\n

______________________________________________________________________<\/p>\n

Reference List<\/strong><\/p>\n

Abdel-Latif MM, Kelleher D and Reynolds JV (2008) Potential role of NF-kB in esophageal adenocarcinoma: as an emerging molecular target. Journal of Surgical Research in press<\/p>\n

Abdel-Latif MM, O’Riordan JM, Ravi N, Kelleher D and Reynolds JV (2005) Activated nuclear factor-kB and cytokine profiles in the esophagus parallel tumor regression following neoadjuvant chemoradiotherapy. Diseases of Esophagus 18: 246-252<\/p>\n

Abraham E (2003) Nuclear factor-kB and its role in sepsis-associated organ failure. Journal of Infectious Diseases 187: S364-S369<\/p>\n

Adler AS, Sinha S, Kawahara TL, Zhang JY, Segal E and Chang HY (2007) Motif module map reveals enforcement of aging by continual NF-kB activity. Genes & Development 21: 3244-3257<\/p>\n

Ahmed KM, Cao N and Li JJ (2006) HER-2 and NF-kB as the targets for therapy-resistant breast cancer. Anticancer Research 26: 4235-4243<\/p>\n

Ahmad R, Raina D, Trivedi V, Ren J, Rajabi H, Kharbanda S and Kufe D (2007) MUC1 oncoprotein activates the IkB kinase beta complex and constitutive NF-kB signaling. Nature Cell Biology 9: 1419-1427<\/p>\n

Allen CT, Ricker JL, Chen Z and Van Waes C (2007) Role of activated nuclear factor-kappaB in the pathogenesis and therapy of squamous cell carcinoma of the head and neck.. Head & Neck 29: 959-971<\/p>\n

Ambili R, Santhi WS, Janam P, Nandakumar K and Pillai MR (2005) Expression of activated transcription factor nuclear factor-kB in periodontally diseased tissues. Journal of Periodontology 76: 1148-1153<\/p>\n

Almeida S, Maillard C, Itin P, Hohl D and Huber M (2008) Five new CYLD mutations in skin appendage tumors and evidence that aspartic acid 681 in CYLD is essential for deubiquitinase activity. Journal of Investigative Dermatology 127: 587-593<\/p>\n

Amiri KI and Richmond A (2005) Role of nuclear factor-kB in melanoma. Cancer Metastasis Reviews 24: 301-313<\/p>\n

Aoki T, Kataoka H, Shimamura M, Nakagami H, Wakayama K, Moriwaki T, Ishibashi R, Nozaki K, Morishita R and Hashimoto N (2007) NF-kB is a key mediator of cerebral aneurysm formation. Circulation 116 2830-2840<\/p>\n

Aoki T, Kataoka H, Ishibashi R, Morishita R and Hashimoto N (2009) Reduced collagen biosynthesis is the hallmark of cerebral aneurysm: contribution of interleukin-1beta and NF-kB. Arteriosclerosis, Thrombosis, and Vascular Biology, in press<\/p>\n

Aradhya S and Nelson DL (2001) NF-kB signaling and human disease. Current Opinions in Genetics and Development 11: 300-306<\/p>\n

Aranha MM, Borralho PM, Ravasco P, Moreira da Silva IKB, Correia L, Fernandes A, Camilo ME and Rodrigues CM (2007) NF-kB and apoptosis in colorectal tumourigenesis. European Journal of Clinical Investigation 37: 416-424<\/p>\n

Arima N and Tei C (2001) HTLV-I Tax related dysfunction of cell cycle regulators and oncogenesis of adult T cell leukemia. Leukemia and Lymphoma 40: 267-278 Leukemia and Lymphoma 40: 267-278<\/p>\n

Arsura M and Cavin LG (2005) Nuclear factor-kB and liver carcinogenesis. Cancer Letters 229: 157-169<\/p>\n

Atreya I, Atreya R and Neurath MF (2008) NF-kB in inflammatory bowel disease. Journal of Internal Medicine 263: 591-596<\/p>\n

Aud D and Peng SL (2006) Mechanisms of disease: transcription factors in inflammatory arthritis. Nature Clinical Practice: Rheumatology 2: 434-442<\/p>\n

Bacher S and Schmitz ML (2004) The NF-kB pathway as a potential target for autoimmune disease therapy. Current Pharmeutical Design 10: 2827-2837<\/p>\n

Baghdiguian S, Martin M, Richard I, Pons F, Astier C, Bourg N, Hay RT, Chemaly R, Halaby G, Loiselet J, Anderson LV, Lopez de Munain A, Fardeau M, Mangeat P, Beckmann JS and Lefranc G (1999) Calpain 3 deficiency is associated with myonuclear apoptosis and profound perturbation of the IkB alpha\/NF-kB pathway in limb-girdle muscular dystrophy type 2A . Nature Medicine 5: 503-511\u00a0 [published erratum appears in Nature Medicine 1999 Jul;5(7):849]<\/p>\n

Baldwin AS Jr (2001) Series introduction: the transcription factor NF-kB and human disease. Journal of Clinical Investigation 107: 3-6<\/p>\n

Bargou RC, Leng C, Krappmann D, Emmerich F, Mapara MY, Bommert K, Royer H-D, Scheidereit C and D\u00f6rken (1996) High-level nuclear NF-kB and Oct-2 is a common feature of cultured Hodgkin\/Reed-Sternberg cells. Blood 87: 4340-4347<\/p>\n

Bargou RC, Emmerich F, Krappmann D, Bommert K, Mapara MY, Arnold W, Royer HD, Grinstein E, Greiner A, Scheidereit C and D\u00f6rkin B (1997) Constitutive NF-kB-RelA activation is required for proliferation and survival of Hodgkin’s disease tumor cells. Journal of Clinical Investigation 100: 2961-2969<\/p>\n

Barnes PJ (2002) New treatments for COPD. Nature Reviews Drug Discovery 1: 437-446<\/p>\n

Baumann B, Weber CK, Troppmair J, Whiteside S, Israel A, Rapp UR and Wirth T (2000) Raf induces NF-kB by membrane shuttle kinase MEKK1, a signaling pathway critical for transformation. Proceedings of the National Academy of Sciences USA 97: 4615-4620<\/p>\n

Bell S, Degitz K, Quirling M, Jilg N, Page S and Brand K (2003) Involvement of NF-kB signalling in skin physiology and disease. Cell Signaling 15: 1-7<\/p>\n

Berenson JR, Ma HM and Vescio R (2001) The role of nuclear factor-kB in the biology and treatment of multiple myeloma. Seminars in Oncology 28: 626-633<\/p>\n

Bertino P, Marconi A, Palumbo L, Bruni BM, Barbone D, Germano S, Dogan AU, Tassi GF, Porta C, Mutti L and Gaudino G (2007) Erionite and asbestos differently cause transformation of human mesothelial cells. International Journal of Cancer 121: 2766-2774<\/p>\n

Besancon F, Atfi A, Gespach C, Cayre YE and Bourgeade MF (1998) Evidence for a role of NF-kB in the survival of hematopoietic cells mediated by interleukin-3 and the oncogenic TEL\/platelet-derived growth factor beta fusion protein.\u00a0 Proceedings of the National Academy of Sciences USA 95: 8081-8086<\/p>\n

Bian X, Opipari Jr AW, Ratanaproeksa AB, Boltano AE, Lucas PC and Castle VP (2002) Constitutively active NF-kB is required for the survival of S-type neuroblastoma. Journal of Biological Chemistry 277: 42144-42150<\/p>\n

Bielory L, Kempuraj D and Theoharides T (2002) Topical immunopharmacology of ocular allergies. Current Opinion in Allergy and Clinical Immunology 2: 435-445<\/p>\n

Bierhaus A, Humpert PM and Nawroth PP (2004) NF-kB as a molecular link between psychosocial stress and organ dysfunction. Pediatic Nephrology 19: 1189-1191<\/p>\n

Bindhu OS, Ramadas K, Sebastian P and Pillai MR (2006) High expression levels of nuclear factor kB and gelatinases in the tumorigenesis of oral squamous cell carcinoma. Head and Neck 28: 916-925<\/p>\n

Brambilla R, Bracchi-Ricard V, Hu WH, Frydel B, Bramwell A, Karmally S, Green EJ and Bethea JR (2005) Inhibition of astroglial nuclear factor kB reduces inflammation and improves functional recovery after spinal cord injury. Journal of Experimental Medicine 202: 145-156<\/p>\n

Brown RE, Tan D, Taylor JS, Miller M, Prichard JW and Kott MM (2007) Morphoproteomic confirmation of constitutively activated mTOR, ERK, and NF-kB pathways in high risk neuroblastoma, with cell cycle and protein analyte correlates. Annals of Clinical and Laboratory Science 37: 141-147<\/p>\n

Brummelkamp TR, Nijman SMB, Cirac AMG and Bernards R (2003) Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kB. Nature 424: 797-801<\/p>\n

Camici M (2007) The Nephrotic Syndrome is an immunoinflammatory disorder. Medical Hypotheses 68: 900-905<\/p>\n

Carbone M and Bedrossian CW (2006) The pathogenesis of mesothelioma. Seminars in Diagnostic Pathology 23: 56-60<\/p>\n

Carrabino S, Carpani D, Livraghi A, Di Cicco M, Costantini D, Copreni E, Colombo C and Conese M (2006) Dysregulated interleukin-8 secretion and NF-kB activity in human cystic fibrosis nasal epithelial cells. Journal of Cystic Fibrosis 5: 113-119<\/p>\n

Cechetto DF (2001) Role of nuclear factor kappaB in neuropathological mechanisms. Progress in Brain Research 132: 391-404<\/p>\n

Celik O, Hascalik S, Elter K, Tagluk ME, Gurates B and Aydin NE (2008) Combating endometriosis by blocking proteasome and nuclear factor kB pathways. Human Reproduction 23: 2458-2465<\/p>\n

Cheah FC, Winterbourn CC, Darlow BA, Mocatta TJ and Vissers MC (2005) Nuclear factor kB activation in pulmonary leukocytes from infants with hyaline membrane disease: associations with chorioamnionitis and ureaplasma urealyticum colonization. Pediatric Research 57: 616-623<\/p>\n

Chen F (2005) Is NF-kB a culprit in type 2 diabetes? Biochemical and Biophysical Research Communications 332: 1-3<\/p>\n

Chen F and Shi X (2002) NF-kB, a pivotal transcription factor in silica-induced diseases. Molecular and Cellular Biochemistry 234-235: 169-176<\/p>\n

Chen K, Long YM, Wang H, Lan L and Liu ZH (2005) Activation of nuclear factor-kappa B and effects of pyrrolidine dithiocarbamate on TNBS-induced rat colitis. World Journal of Gastroenterology 11: 1508-1514<\/p>\n

Chen RF, Li ZH, Kong XH and Chen JS (2005) Effect of mutated IkBa transfection on multidrug resistance in hilar cholangiocarcinoma cell lines. World Journal of Gastroenterology 11: 726-728<\/p>\n

Christman JW, Sadikot RT and Blackwell TS (2000) The role of nuclear factor-kB in pulmonary diseases. Chest 117: 1482-1487<\/p>\n

Chung CH, Parker JS, Ely K, Carter J, Yi Y, Murphy BA, Ang KK, El-Naggar AK, Zanation AM, Cmelak AJ, Levy S, Slebos RJ and Yarbrough WG (2006) Gene expression profiles identify epithelial-to-mesenchymal transition and activation of nuclear factor-kB signaling as characteristics of a high-risk head and neck squamous cell carcinoma. Cancer Research 66 8210-8218<\/p>\n

Chung HY, Kim HJ, Kim KW, Choi JS and Yu BP (2002) Molecular inflammation hypothesis of aging based on the anti-aging mechanism of calorie restriction. Microscopy Research and Technique 59: 264-272<\/p>\n

Collister KA and Albensi BC (2005) Potential therapeutic targets in the NF-kB pathway for Alzheimer’s disease. Drug News Perspectives 18: 623-629<\/p>\n

Corbetta S, Vicentini L, Ferrero S, Lania A, Mantovani G, Cordella D, Beck-Peccoz P and Spada A (2005) Activity and function of the nuclear factor kB pathway in human parathyroid tumors. Endocrine Related Cancer 12: 929-937<\/p>\n

Courtois G and Israel A (2000) NF-kB defects in humans: the NEMO\/incontinentia pigmenti connection. Sci STKE Nov 14 (58): PE1<\/p>\n

Cousins DJ, McDonald J and Lee TH (2008) Therapeutic approaches for control of transcription factors in allergic disease. Journal of Allergy and Clinical Immunology 121 803-809<\/p>\n

Csizar A, Wang M, Lakatta EG and Ungvari ZI (2008) Inflammation and endothelial dysfunction during aging: role of NF-kB. Journal of Applied Physiology, in press<\/p>\n

Davis RE, Brown KD, Siebenlist U and Staudt LM (2001) Constitutive nuclear factor kB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. Journal of Experimental Medicine 194: 1861-1874<\/p>\n

Dejardin E, Deregowski V, Chapelier M, Jacobs N, Gielen J, Merville M-P and Bours (1999) Regulation of NF-kB activity by IkB-related proteins in adenocarcinoma cells. Oncogene 18: 2567-2577<\/p>\n

Dijkstra G, Moshage H and Jansen PL (2002) Blockade of NF-kB activation and donation of nitric oxide: new treatment options in inflammatory bowel disease? Scandinavian Journal of Gastroenterology Supplement 236: 37-41<\/p>\n

Domenyuk VP, Litovkin KV, Verbitskaya TG, Dubinia VGa dn Bubnov VV (2007) Identification of new DNA markers of endometrial cancer in patients from the Ukranian population. Experimental Oncology 29 85-93<\/p>\n

Du MQ (2007) MALT lymphoma: recent advances in aetiology and molecular genetics. Journal of Clinical and Experimental Hematology 47: 31-42<\/p>\n

Eldor R, Yeffet YK, Baum K, Doviner V, Amar D, Ben-Neriah Y, Christofon G, Peled A, Carel JC, Boitard C, Klein T, Serup P, Eizirik DL and Melloul D (2006) Conditional and specific NF-kB blockade protects pancreatic beta cells from diabetogenic agents. Proceedings of the National Academy of Sciences USA 103: 5072-5077<\/p>\n

Fabre C, Carvalho G, Tasdemir E, Braun T, Ades L, Grosjean J, Boehrer S, Metivier D, Souquere S, Pierron G, Fenaux P and Kroemer G (2007) NF-kB inhibition sensitizes to starvation-induced cell death in high-risk myelodysplastic syndrome and acute myeloid leukemia. Oncogene 26: 4071-4083<\/p>\n

Finco TS, Westwick JK, Norris JL, Beg AA, Der CJ and Baldwin Jr AS (1997) Oncogenic Ha-Ras-induced signaling activates NF-kB transcriptional activity, which is required for cellular transformation. Journal of Biological Chemistry 272: 24113-24116<\/p>\n

Fox CJ, Hammerman PS, Cinalli RM, Master SR, Chodosh LA and Thompson CB (2003) The serine\/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor. Genes & Development 17: 1841-1854<\/p>\n

Fradet V, Lessard L, Begin LR, Karakiewicz P, Masson AM and Saad F (2004) Nuclear factor-kB nuclear localization is predictive of biochemical recurrence in patients with positive margin prostate cancer. Clinical Cancer Research 10: 8460-8464<\/p>\n

Frantz S, Fraccarollo D, Wagner H, Behr TM, Jung P, Angermann CE, Ertl G, Bauersachs J (2003) Sustained activation of nuclear factor kappaB and activator protein 1 in chronic heart failure. Cardiovascular Research 57: 749-756<\/p>\n

Freund C, Schmidt-Ullrich R, Baurand A, Dunger S, Schneider W, Loser P, El-Jamali A, Dietz R, Scheidereit C and Bergmann MW (2005) Requirement of nuclear factor-kB in angiotensin II- and isoproterenol-induced cardiac hypertrophy in vivo. Circulation 111: 2319-2325<\/p>\n

Furman RR, Asgary Z, Mascarenhas JO, Liou HC and Schattner EJ (2000) Modulation of NF-kB activity and apoptosis in chronic lymphocytic leukemia B cells. Journal of Immunology 164: 2200-2206<\/p>\n

Garkavtsev I, Kozin SV, Chernova O, Xu L, Winkler F, Brown E, Barnett GH and Jain RK (2004) The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis. Nature 428: 328-332<\/p>\n

Gil A, Aguilera CM, Gil-Campos M and Canete R (2007) Altered signalling and gene expression associated with the immune system and the inflammatory response in obesity. British Journal of Nutition 98: S121-S126<\/p>\n

Gilmore TD (2007) Multiple myeloma: lusting for NF-kB. Cancer Cell 12 95-97\u2028\u2028\u00a0 \u00a0\u00a0Gilmore TD, Gapuzan M-E, Kalaitzidis D and Starczynowski D (2002) Rel\/NF-kB\/IkB signal transduction in the generation and treatment of human cancer. Cancer Letters 181: 1-9<\/p>\n

Gombos K, Zele E, Kiss I, Varjas T, Puskas L, Kozma L, Juhasz F, Kovacs E, Szanyi I and Ember I (2007) Characterization of microarray gene expression profiles of early stage thyroid tumours. Cancer Genomics and Proteomics 4: 403-410<\/p>\n

Gong KZ, Song G, Speirs JP, Kelso EJ and Zhang ZG (2007) Activation of immune and inflammatory systems in chronic heart failure: novel therapeutic approaches. International Journal of Clinical Practice 61: 611-621<\/p>\n

Gonzalez-Ramos R, Donnez J, Defrere S, Leclercq I, Squifflet J, Lousse JC and Van Langendonckt A (2007) Nuclear factor-kB is constitutively activated in peritoneal endometriosis. Molecular Human Reproduction in press<\/p>\n

Gray KD, Simovic MO, Blackwell TS, Christman JW, May AK, Parman KS, Chapman WC and Stain SC (2006) Activation of nuclear factor kB and severe hepatic necrosis may mediate systemic inflammation in choline-deificient\/ethionine-supplemented diet-induced pancreatitis. Pancrease 33: 260-267<\/p>\n

Greetham D, Ellis CD, Mewar D, Fearon U, Nic An Ultaigh S, Veale DJ, Guesdon F and Wilson AG (2007) Functional characterisation of NF-kB inhibitor-like protein 1 (NFkBIL1), a candidate susceptibility gene for rheumatoid arthritis. Human Molecular Genetics, in press<\/p>\n

Guijarro C and Egido J (2001) Transcription factor-kappaB (NF-kB) and renal disease. Kidney International 59: 415-424<\/p>\n

Guo SW (2006) Nuclear factor-kB (NF-kB): an unsuspected major culprit in the pathogenesis of endometriosis that is still at large. Gynecology and Obstetrics Investigations 63: 71-97<\/p>\n

Guzik TJ and Harrison DG (2007) Endothelial NF-kB as a mediator of kidney damage: the missing link between systemic vascular and renal disease?\u00a0 Circulation Research 101: 227-229<\/p>\n

Guzman ML, Neering SJ, Upchurch D, Grimes B, Howard DS, Rizzieri DA, Luger SM and Jordan CT (2001) Nuclear factor-kB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 98: 2301-2307<\/p>\n

Hammerman PS, Fox CJ, Cinalli RM, Xu A, Wagner JD, Lindsten T and Thompson CB (2004) Lymphocyte transformation by Pim-2 is dependent on nuclear factor-kB activation. Cancer Research 64: 8341-8348<\/p>\n

Hang CH, Shi JX, Li JS, Li WQ and Yin HX (2005) Up-regulation of intestinal nuclear factor kB and intercellular adhesion molecule-1 following traumatic brain injury in rats. World Journal of Gastroenterology 11: 1149-1154<\/p>\n

Hasselgren PO (2007) Ubiquitination, phosphorylation and acetylation – triple threat in muscle wasting. Journal of Cellular Physiology 293: R1545-R1551<\/p>\n

Hayashi T and Faustman D (2002) Defective function of the proteasome in autoimmunity: involvement of impaired NF-kB activation. Diabetes Technology & Therapeutics 2: 415-428<\/p>\n

Hayashi S, Yamamoto M, Ueno Y, Ikeda K, Ohshima K, Soma G and Fukushima T (2001) Expression of nuclear factor-kB, tumor necrosis factor receptor type 1, and c-Myc in human astrocytomas. Neurologia Medico-Chirufica 41: 187-195<\/p>\n

Heinemann S, Biesinger B, Fleckenstein B and Albrecht JC (2006) NF-kB signaling is induced by the oncoprotein tio through direct interaction with TRAF6. Journal of Biological Chemistry 281: 8565-8572<\/p>\n

Herrmann O, Baumann B, de Lorenzi R, Muhammad S, Zhang W, Kleesiek J, Malfertheiner M, Kohrmann M, Potrovita I, Maegele I, Beyer C, Bruke JR, Hasan MT, Bujard H, Wirth T, Pasparakis M and Schwaninger M (2005) IKK mediates ischemia-induced neuronal death. Nature Medicine 11: 13322-1329<\/p>\n

Herwamana S, Albhazal S, Lin TT, Clement M, Jenkins C, Guzman ML, Jordan CT, Neelakantan S, Crooks PA, Burnett AK, Pratt G, Fegan C, Rowntree C, Brennaan P and Pepper C (2008) The NF-kB subunit, Rel A, is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukaemia and represents a promising therapeutic target. Blood in press<\/p>\n

Hettne KM, de Mos M, de Bruijn AG, Weeber M, Boyer S, van Mulligen EM, Cases M, Mestres J and van der Lei J (2007) Applied information retrieval and multidisciplinary research: new mechanistic hypotheses in Complex Regional Pain Syndrome. Journal of Biomedical Discovery and Collaboration 2: 2<\/p>\n

Hiscott J, Kwon H and Genin P (2001) Hostile takeovers: viral appropriation of the NF-kB pathway. Journal of Clinical Investigation 107: 143-151<\/p>\n

Ho E and Bray TM (1999) Antioxidants, NFkB activation, and diabetogenesis. Proceedings of the Society of Experimental Biology and Medicine 222: 205-213<\/p>\n

Ho L, Davis RE, Conne B, Chappuis R, Berczy M, Mhawech P, Staudt LM and Schwaller J (2005) MALT1 and the API2-MALT1 fusion act between CD40 and IKK and confer NF-kB dependent proliferative advantage and resistance against FAS-induced cell death in B cells. Blood 105: 2891-2899<\/p>\n

Holcomb B, Yip-Schneider M and Schmidt CM (2008) The role of nuclear factor kappaB in pancreatic cancer and the clinical applications of targeted therapy. Pancrease 36: 225-235<\/p>\n

Holmes-McNary M (2002) Nuclear factor kappaB signaling in catabolic disorders. Current Opinion in Clinical Nutrition and Metabolic Care 5: 255-263<\/p>\n

Horie R, Watanabe T and Umezawa K (2006) blocking NF-kB as a potential strategy to treat adult T-cell leukemia\/lymphoma. Drug News & Perspectives 19: 201-209<\/p>\n

Horiguchi Y, Kuroda K, Nakashima J, Murai M and Umezawa K (2003) Antitumor effect of a novel nuclear factor-kB activation inhibitor in bladder cancer cells. Expert Reviews in Anticancer Therapy 3: 793-798<\/p>\n

Huang S, Pettaway CA, Uehara H, Bucana CD and Fidler IJ (2001) Blockade of NF-kB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 20: 4188-4197<\/p>\n

Huang S, Robinson JB, DeGuzman A, Bucanna CD and Fidler IJ (2000) Blockade of nuclear factor-kB signaling inhibits angiogenesis and tumorigenicity of ovarian cancer cells by suppressing expression of vascular endothelial growth factor and Interleukin 8. Cancer Research 60: 5334-5339<\/p>\n

Inagaki H (2007) Mucosa-associated lymphoid tissue lymphoma: Molecular pathogenesis and clinicopathological significance. Pathology International 57: 474-484<\/p>\n

Jackson L and Evers BM (2006) Chronic inflammation and pathogenesis of GI and pancreatic cancers. Cancer Treatment and Research 130: 39-65<\/p>\n

Jackson-Bernitsas DG, Ichikawa H, Takada Y, Myers JN, Lim XL, Darnay BG, Chaturvedi MM and Aggarwal BB (2007) Evidence that TNF-TNFR1-TRADD-TRAF2-RIP-TAK1-IKK pathway mediates constitutive NF-kB activation and proliferation in human head and neck squamous cell carcinoma. Oncogene 26: 1385-1397<\/p>\n

Jeru I, Duquesnoy P, Fernandes-Alnemri T, Cochet E, Yu JW, Lackmy-Port-Lis M, Grimpel E, Landman-Parker J, Hentgen V, Marlin S, McElreavey K, Sarkisian T, Grateau G, Alnemri ES and Amselem S (2008) Mutations in NALP12 cause hereditary fever syndromes. Proceedings of the National Academy of Sciences USA in press<\/p>\n

Jin X, Wang Z, Qiu L, Zhang D, Guo Z, Gao Z, Deng C, Wang F, Wang S and Guo C (2008) Potential biomarkers involving IKK\/RelA signal in early stage non-small cell lung cancer. Cancer Science in press<\/p>\n

Kadhim HS, AL-Jeboori TI and Tawfik MS (2006) Possible role of nuclear factor kB detected by in situ hybridization in the pathogenesis of transitional cell carcinoma of the bladder. Journal Medical Lebanais 54: 96-99<\/p>\n

Karin M, Cao Y, Greten FR and Li ZW (2002) NF-kB in cancer: from innocent bystander to major culprit. Nature Reviews Cancer 2: 301-310<\/p>\n

Kammer GM and Tsokos GC (2002) Abnormal T lymphocyte signal transduction in systemic lupus erythematosus. Current Directions in Autoimmunity 5: 131-150<\/p>\n

Khoshnan A, Ko J, Watkin EE, Paige LA, Reinhart PH and Patterson PH (2004) Activation of the IkB kinase complex and nuclear factor-kB contributes to mutant Huntingtin neurotoxicity. Journal of Neuroscience 24: 7999-8008<\/p>\n

Kitaoka Y, Kumai T, Kitaoka Y, Lam TT, Munemasa Y, Isenoumi K, Motoki M, Kuribayashi K, Kogo J, Kobayashi S and Ueno S (2004) Nuclear factor-kB p65 in NMDA-induced retinal neurotoxicity. Brain Research Molecular Brain Research 131: 8-16<\/p>\n

Knecht H, Berger C, Rothenberger S, Odermatt BF and Brousset P (2001) The role of Epstein-Barr virus in neoplastic transformation. Oncology 60: 289-302<\/p>\n

Kobielak A & Fuchs E (2006) Links between alpha-catenin, NF-kB, and squamous cell carcinoma. Proceedings of the National Academy of Sciences 103: 2322-2327<\/p>\n

Kordes U, Krappmann D, Heissmeyer V, Ludwig WD and Scheidereit C (2000) Transcription factor NF-kB is constitutively active in acute lymphoblastic leukemia cells. Leukemia 14: 399-402<\/p>\n

Kovalenko A, Chabie-Bessia C, Cantarella G, Israel A, Wallach D and Courtois G (2003) The tumour suppressor CYLD negatively regulates NF-kB signalling by deubiquitination. Nature 424: 801-805<\/p>\n

Kumar A, Takada Y, Boriek AM and Aggarwal BB (2004) Nuclear factor-kB: its role in health and disease. Journal of Molecular Medicine 82: 434-448<\/p>\n

Kumar B, Husain SA and Chandra B (2005) Constitutive activation of nuclear factor-kB: Preferential homodimerization of p50 subunits in cervical carcinoma. Frontiers in Bioscience 10: 1510-1519<\/p>\n

Lavie L (2003) Obstructive sleep apnoea syndrome – an oxidative stress disorder. Sleep Medicine Review 7: 35-51<\/p>\n

Lee BL, Lee HS, Jung J, Cho SJ, Chung HY, Kim WH, Jin YW, Kim CS and Nam SY (2005) Nuclear factor-kB activation correlates with better prognosis and Akt activation in human gastric cancer. Clinical Cancer Research 11 2518-2525<\/p>\n

Lee CH, Jeon YT, Kim SH and Song YS (2007) NF-kB as a potential molecular target for cancer therapy. Biofactors 29: 19-35<\/p>\n

Lehrke M, Reilly MP, Millington SC, Iqbal N, Rader DJ and Lazar MA (2004) An inflammatory cascade leading to hyperresistinemia in humans. PLoS Medicine 1: e45<\/p>\n

Lei HY and Zhao XL (2007) Clincal significance of NF-kB continual activity and expression of WT1 and MDR1 in acute nonlymphocytic leukemia. Zhongguo Shi Yan Xue Za Zhi 15 253-257<\/p>\n

Leleu X, Eeckhoute J, Jia X, Roccaro AM, Moreau AS, Farag M, Sacco A, Ngo HT, Runnels J, Melham MR, Burwick N, Azab A, Azab F, Hunter Z, Hatjiharissi E, Carrasco DR, Treon SP, Witzip TE, Hideshima T, Brown M, Anderson KC and Ghobrial IM (2008) Targeting NF-kB in Waldenstrom macroglobulinemia. Blood in press<\/p>\n

Lessard L, Karakiewicz PI, Bellon-Gagnon P, Alam-Fahmy M, Ismail HA, Mes-Masson AM and Saad F (2006) Nuclear localization of nuclear factor-kB p65 in primary prostate tumors is highly predictive of pelvic lymph node metastases. Clinical Cancer Research 12: 5741-5745<\/p>\n

Levidou G, Korkolopoulou P, Nikiteas N, Tzanakis N, Thymara I, Saetta AA Tsigris C, Rallis G, Vlasis K and Patsouris E (2007) Expression of nuclear factor kB in human gastric carcinoma: relationship with IkBa and prognostic significance. Virchows Archiv 450: 519-527<\/p>\n

Levidou G, Saetta AA, Korkolopoulou P, Papanastasiou P, Gioti K, Pavlopoulos P, Diamantopoulou K, Thomas-Tsagli E, Xiromeritis K and Patsouris E (2008) Clinical significance of nuclear factor (NF)-kB levels in urothelial carcinoma of the urinary bladder. Virchows Archiv in press<\/p>\n

Li JJ and Gao RL (2005) Should atherosclerosis be considered a cancer of the vascular wall? Medical Hypotheses 64: 694-698<\/p>\n

Lin N, Uchi H, Moroi Y, Fukiwake N, Dainichi T, Takeuchi S, Takahara M, Tu Y, Furue M and Urabe K (2007) Expression of the p38 MAPK, NF-kB and cyclin D1 in extramammary Paget’s disease. Journal of Dermatological Science 45: 187-192<\/p>\n

Lind DS, Hochwald SN, Malaty J, Rekkas S, Hebig P, Mishra G, Moldawer LL, Copeland EM 3rd<\/sup> and Mackay S (2001) Nuclear factor-kB is upregulated in colorectal cancer. Surgery 130: 363-369<\/p>\n

Liu J, Kumar KGS, Yu D, Molton SA, McMahon M, Herlyn M, Thomas-Tikhonenko A and Fuchs SY (2007) Oncogenic BRAF regulates beta-Trcp expression and NF-kB activity in human melanoma cells. Oncogene 26: 1954-1958<\/p>\n

Loercher A, Lee TL, Ricker JL, Howard A, Geoghegen J, Chen Z, Sunwoo JB, Sitcheran R, Chuang EY, Mitchell JB, Baldwin AS Jr and Van Waes C (2004) Nuclear factor-kB is an important modulator of the altered gene expression profile and malignant phenotype in squamous cell carcinoma. Cancer Research 64: 6511-6523<\/p>\n

Lopez-Pedrera C, Buendia P. Jose Cuadrado M, Siendones E, Angeles Aguire M, Barbarroja N, Montiel-Duarte C, Torres A, Khamashta M and Velasco F (2005) Antiphospholipid antibodies from patients with the antiphospholipid syndrome induce monocyte tissue factor expression through the simultaneous activation of NF-kB\/Rel proteins via the p38 mitogen-activated protein kinase pathway, and of the MEK-1\/ERK pathway. Arthritis and Rheumatism 54: 301-311<\/p>\n

Lucas PC, Kuffa P, Gu S, Kohrt D, Kim DS, Siu K, Jin X, Swenson J and McAllister-Lucas LM (2007) A dual role for the API2 moiety in API2-MALT1-dependent NF-kB activation: heterotypci oligomerization and TRAF2 recruitment. Oncogene in press<\/p>\n

Madjdpour L, Kneller S, Booy C, Pasch T, Schimmer RC and Beck-Schimmer B (2003) Acid-induced lung injury: role of Nuclear Factor-kB. Anesthesiology 99: 1323-1332<\/p>\n

Maes M, Mihaylova I and Bosmans E (2007) Not in the mind of the neurasthenic lazybones but in the cell nucleus: patients with chronic fatigue syndrome have increased production of nuclear factor kappaB. Neuro Endocinol Letters 28: 456-462<\/p>\n

Mammon K, Keshet R, Savion S, Pekar O, Zaslavsky Z, Fein A, Toder V and Torchinsky A (2005)\u00a0 Diabetes-induced fetal growth retardation is associated with suppression of NF-kB activity in embryos. Review of Diabetic Studies 2 27-34<\/p>\n

Martinez N, Camacho FI, Algara P, Rodriguez A, Dopazo A, Ruiz-Ballesteros E, Martin P, Martinez-Climent JA, Garcia-Conde J, Menarguez J, Solano F, Mollejo M and Piris MA (2003) The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival. Cancer Research 63: 8226-8232<\/p>\n

Mattson MP and Camandola S (2001) NF-kB in neuronal plasticity and neurodegenerative disorders. Journal of Clinical Investigation 107: 247-254<\/p>\n

Mazzeo A, Aguennouz M, Messina C and Vita G (2004) Immunolocalization and activation of transcription factor nuclear factor kB in dysimmune neuropathies and familial amyloidotic polyneuropathy. Archives of Neurology 61: 1097-1102<\/p>\n

Merchant SN, Adams JC and\u00a0 Nadol JB Jr (2005) Pathology and pathophysiology of idiopathic sudden sensorineural hearing loss. Otology and Neurotology 26: 151-160<\/p>\n

Min R, Tong J, Wenjun Y, Wenhu D, Xiaojian Z, Jiacai H, Jian Z, Wantao C and Chenping Z (2007) Growth inhibition and induction of apoptosis in human oral squamous cell carcinoma Tca-8113 cell lines by shikonin was partly through the inactivation of NF-kB pathway. Phytotherapy Research in press<\/p>\n

Mishra A, Bharti AC, Varghese P, Saluja D and Das BC (2006) Differential expression and activation of NF-kB family proteins during oral carcinogenesis: role of high risk human papillomavirus infection. International Journal of Cancer 119: 2840-2850<\/p>\n

Mogi M, Kondo T, Mizuno T and Nagatsu T (2007) p53 protein, interferon-gamma, and NF-kB levels are elevated in the Parkinsonian brain. Neuroscience Letters 414: 94-97<\/p>\n

Motadi LR, Misso NL, Dlamini Z and Bhoola KD (2007) Molecular genetics and mechanisms of apoptosis in carcinomas of the lung and pleura: therapeutic targets. International Immunopharmacology 7: 1934-1947<\/p>\n

Munzert G, Kirchner D, Ottmann O, Bergmann L and Schmid RM (2004) Constitutive NF-kB\/Rel activation in philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL). Leukemia and Lymphoma 45: 1181-1184<\/p>\n

Nair A, Venkatraman M, Maliekal TT, Nair B and Karunagaran D (2003) NF-kB is constitutively activated in high- grade squamous intraepithelial lesions and squamous cell carcinomas of the human uterine cervix. Oncogene 22: 50-58<\/p>\n

Nakayama H, Ikebe T, Beppu M and Shirasuma K (2001) High expression levels of nuclear factor kB, IkB kinase b and Akt kinase in squamous cell carcinoma of the oral cavity. Cancer 92: 3037-3044<\/p>\n

Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet Jr RJ and Sledge Jr GW (1997) Constitutive activation of NF-kB during progression of breast cancer to hormone-independent growth. Molecular and Cellular Biology 17: 3629-3639<\/p>\n

Niederberger E and Geisslinger G (2008) The IKK-NF-kB pathway: a source for novel molecular drug targets in pain therapy? FASEB Journal, in press<\/p>\n

Neurath MF, Becker C and Barbulescu K (1998) Role of NF-kB in immune and inflammatory responses in the gut. Gut 43: 856-860<\/p>\n

Nichols TC, Fischer TH, Deliargyris EN and Baldwin Jr AS (2001) Role of nuclear factor-kappaB (NF-kB) in inflammation, periodontitis, and atherogenesis. Annals of Periodontology 6: 20-29<\/p>\n

Nichols TC (2004) NF-kB and reperfusion injury. Drug News and Perspectives 17: 99-104<\/p>\n

Oikonomidou O, Vlachoyiannopoulos PG, Kominakis A, Kalofoutis A, Moutsopoulos HM and Moutsatsou P (2007) Glucocorticoid receptor, nuclear factor kB, activator protein-1 and c-Jun N-terminal kinase in systemic lupus erythematosus patients. Neuroimmunomodulation 13 194-204<\/p>\n

Okamoto T (2006) NF-kB and rheumatic diseases. Endocrine, Metabolic & Immune Disorders: Drug Targets 6: 359-372<\/p>\n

Ondrey FG, Dong G, Sunwoo J, Chen Z, Wolf JS, Crowl-Bancroft CV, Mukaida N and Van Waes C (1999) Constitutive activation of transcription factors NF-kB, AP-1, and NF-IL6 in human head and neck squamous cell carcinoma cell lines that express pro-inflammatory and pro-angiogenic cytokines. Molecular Carcinogenesis 26: 119-129<\/p>\n

Onen F (2006) Familial Mediterranean Fever. Rheumatology International 26: 489-496<\/p>\n

O’Neil BH, Buzkova P, Farrah H, Kashatus D, Sanoff H, Goldberg RM, Baldwin AS and Funkhouser WK (2007) Expression of nuclear factor-kB family proteins in hepatocellular carcinomas. Oncology 72: 97-104<\/p>\n

Oya M, Ohtsubo M, Takayanagi A, Tachibana M, Shimizu N and Murai M (2001) Constitutive activation of NF-kB prevents TRAIL-induced apoptosis in renal cancer cells. Oncogene 20: 3888-3896<\/p>\n

Oya M, Takayanagi A, Horiguchi A, Mizuno R, Ohtsubo M, Marumo K, Shimizu N and Murai M (2003) Increased nuclear factor kappaB activation is related to tumor development of renal cell carcinoma. Carcinogenesis 24: 377-384<\/p>\n

Pacifico F and Leonardi A (2006) NF-kB in solid tumors. Biochemical Pharmacology 72: 1142-1152<\/p>\n

Pacifico F, Mauro C, Barone C, Crescenzi E, Mellone S, Monaco M, Chiappetta G, Terrazzano G, Liguoro D, Vito P, Consiglio E, Formisano S and Leonardi A (2004) Oncogenic and anti-apoptotic activity of NF-kB in human thyroid carcinomas. Journal of Biological Chemistry 279: 54610-54619<\/p>\n

Pahl A and Szelenyi I (2002) Asthma therapy in the new millennium. Inflammation Research 51: 273-282<\/p>\n

Palayoor ST, Yourmell MY, Calderwood SK, Coleman CN and Price BD (1999) Constitutive activation of IkB kinase b and NF-kB in prostate cancer cells is inhibited by ibuprofen. Oncogene 18: 7389-7394<\/p>\n

Pallares J, Martinez-Guitarte JL, Dolcet X, Llobet D, Rue M, Palacios J, Prat J and Matias-Guiu X (2004) Abnormalities in the NF-kB family and related proteins in endometrial carcinoma. Journal of Pathology 204: 595-577<\/p>\n

Palmby TR, Abe K, Karnoub AE and Der CJ (2005) Vav transformation requires activation of multiple GTPases and regulation of gene expression. Molecular Cancer Research 2: 702-711<\/p>\n

Pan S, Tao Z, Wu L, Xiao B and Chen S (2005) Nuclear factor kB\/p65 and cyclooxygenase-2 expression and clinic significance in human laryngeal squamous cell carcinoma [Article in Chinese]. Lin Chuang Er Bi Yan Hou Ke Za Zhi 19: 535-537<\/p>\n

Park Gy and Christman JW (2006) Nuclear factor kB is a promising therapeutic target in inflammatory lung disease. Current Drug Targets 7: 661-668<\/p>\n

Paule B, Terry S, Kheuang L, Soyeux P, Vacherot F and de la Taille A (2007) The NF-kB\/IL-6 pathway in metastatic androgen-independent prostate cancer: new therapeutic approaches? World Journal of Urology 25: 477-489<\/p>\n

Pena AS and Penate M (2002) Genetic susceptibility and regulation of inflammation in Crohn’s disease. Relationship with the innate immune system [Article in English, Spanish]. Revista Espanola d Enfermedades Digestivas 94: 351-360<\/p>\n

Pennington C, Dunn J, Li C, Ha T and Browder W (2000) Nuclear factor kB activation in acute appendicitis: a molecular marker for extent of disease? American Surgery 66: 914-918<\/p>\n

Pickering BM, de Mel S, Lee M, Howell M, Habens F, Dallman CL, Neville LA, POtter KN, Mann J, Mann DA, Johnson PW, Stevenson FK and Packham G (2007) Pharmacological inhibitors of NF-kB accelerate apoptosis in chronic lymphocytic leukaemia cells. Oncogene 26: 1166-1177<\/p>\n

Pizzi M and Spano P (2006) Distinct roles of diverse nuclear factor kB complexes in neuropathological mechanisms. European Journal of Pharmacology 545: 22-28<\/p>\n

Pollard HB, Ji XD, Jozwik C and Jacobowitz DM (2005) High abundance protein profiling of cystic fibrosis lung epithelial cells. Proteomics 5: 2210-2216<\/p>\n

Puel A, Yang K, Ku CL, von Bernuth H, Bustamante J, Santos OF, Lawrence T, Chang HH, Al-Mousa H, PIcard C and Casonova JL (2005)\u00a0 Heritable defects of the human TLR signalling pathways. Journal of Endotoxin Research 11: 220-224<\/p>\n

Purcell NH and Molkentin JD (2003) Is nuclear factor kappaB an attractive therapeutic target for treating cardiac hypertrophy? Circulation 108: 638-640<\/p>\n

Qiao L, Zhang H, Yu J, Francisco R, Dent P, Ebert MP, Rocke C and Farrell G (2006) Constitutive activation of NF-kB in human hepatocellular carcinoma: evidence of a cytoprotective role. Human Gene Therapy 17 280-290<\/p>\n

Rahman I and Kilty I (2006) Antioxidant therpaeutic targets in COPD. Current Drug Targets 7: 707-720<\/p>\n

Ramdass B, Maliekal TT, Lakshmi S, Rehman M, Rema P, Nair P, Mukherjee G, Reddy BK, Krishna S and Radakrishna Pillai M (2007) Coexpression of Notch1 and NF-kB signalling pathway components in human cervical cancer progression. Gynecologic Oncology 104: 352-361<\/p>\n

Raychaudhuri B, Han Y, Lu T and Vogelbaum MA (2007) Aberrant constitutive activation of nuclear factor kB in glioblastoma multiforme drives invasive phenotype. Journal of Neurooncology 85: 39-47<\/p>\n

Reuter U, Chiarugi A, Bolay H and Moskowitz MA (2006) Nuclear factor-kB a s a molecular target for migraine therapy. Headache 43: 426-427<\/p>\n

Reuther JY, Reuther GW, Cortez D, Pendergast AM and Baldwin Jr AS (1998)\u00a0 A requirement for NF-kB activation in Bcr-Abl mediated transformation. Genes & Development 12: 968-981<\/p>\n

Ridder DA, Schwaninger M (2008) NF-kB signaling in cerebral ischemia. Neuroscience in press<\/p>\n

Ritchie ME (1998) Nuclear factor kappaB is markedly and selectively activated in humans with unstable angina pectoris. Circulation 98: 1707-1713<\/p>\n

Roman-Blas JA and Jimenez SA (2006) NF-kB as a potential therapeutic target in osteoarthritis and rheumatoid arthritis. Osteoarthritis\u00a0 and Cartilage 14 839-848<\/p>\n

Roshak AK, Callahan JF and Blake SM (2002) Small-molecule inhibitors of NF-kB for the treatment of inflammatory joint disease. Current Opinion in Pharmacology 2: 316-321<\/p>\n

Ross JS, Stagliano NE, Donovan MJ, Breitbart RE and Ginsburg GS (2001) Atherosclerosis: a cancer of the blood vessels? American Journal of Clinical Pathology 116: S97-S107<\/p>\n

Rottner M, Kunzelmann C, Mergey M, Freyssinet JM and Martinez MC (2007) Exaggerated apoptosis and NF-kB activation in pancreatic and tracheal cystic fibrosis cells. FASEB Journal 21: 2939-2948<\/p>\n

Russell JP, Shinohara S, Melillo RM, Castellone MD, Santoro M and Rothstein JL (2003) Tyrosine kinase oncoprotein, RET\/PTC3, induces the secretion of myeloid growth and chemotactic factors. Oncogene 22: 4569-4577<\/p>\n

Santos SC, Monni R, Bouchaert I, Bernard O, Gisselbrecht S, Gouilleux F and Penard-Lacronique V (2001) Involvement of the NF-kB pathway in the transforming properties of the TEL-Jak2 leukemogenic fusion protein. FEBS Letters 497: 148-152<\/p>\n

Sagaert X, De Wolf-Peeters C, Noels H and Baens M (2007) The pathogenesis of MALT lymphomas: where do we stand? Leukemia 21: 389-396<\/p>\n

Sarkar FH, Banerjee S and Li Y (2006) Pancreatic cancer: pathogenesis, prevention and treatment. Toxicology and Applied Pharmacology in press<\/p>\n

Sasaki N, Morisaki T, Hashizume K, Yao T, Tsuneyoshi M, Noshiro H, Nakamura K, Yamanaka T, Uchiyama A, Tanaka M and Katano M (2001) Nuclear factor-kB p65 (RelA) transcription factor is constitutively activated in human gastric carcimoma tissue. Clinical Cancer Research 7: 4136-4142<\/p>\n

Satoh JI, Illes Z, Peterfalvi A, Tabunoki H, Rozsa C and Yamamura T (2007) Aberrant transcriptional regulatory network in T cells of multiple sclerosis. Neuroscience Letters 422: 30-33<\/p>\n

Sawada H, Mitani Y, Maruyama J, Jiang BH, Ikeyama Y, Dida FA, Yamamoto H, Imanaka-Yoshida K, Shimpo H, Mizoguchi A, Maruyama K and Komada Y (2007) A nuclear factor-kB inhibitor pyrrolidine dithiocarbamate ameliorates pulmonary hypertension in rats. Chest 132: 1265-1274<\/p>\n

Sawhney M, Rohatgi N, Kaur J, Shishodia S, Sethi G, Gupta SD, Deo SV, Shukla NK, Aggarwal BB and Ralhan R (2007) Expression of NF-kB parallels COX-2 expression in oral precancer and cancer: Association with smokeless tobacco. International Journal of Cancer 120: 2545-2556<\/p>\n

Sclabas GM, Fujioka S, Schmidt C, Evans DB and Chiao PJ (2003) NF-kB in pancreatic cancer. International Journal of Gastrointestinal Cancer 33: 15-26<\/p>\n

Schottelius AJ and Dinter H (2006) Cytokines, NF-kB, microenvironment, intestinal inflammation and cancer. Cancer Treatment and Research 130: 67-87<\/p>\n

Sebens S, Arlt A and Schafer H (2008) NF-kB as a molecular target in the therapy of pancreatic cancer. Recent Results in Cancer Research 177: 151-164<\/p>\n

Seki E, and Brenner DA (2007) The role of NF-kB in hepatocarcinogenesis: promoter or suppressor? Journal of Hepatology 47: 307-309<\/p>\n

Sen CK and Roy S (2005) Relief from a heavy heart: redox-sensitive NF-kB as a therapeutic target in managing cardiac hypertrophy. American Journal of Physiology: Heart and Circulatory Physiology 289: H17-H19<\/p>\n

Seppanen M and Vihko KK (2000) Activation of transcription factor NF-kB by growth inhibitory cytokines in vulvar carcinoma cells. Immunology Letters 74: 103-109<\/p>\n

Shaffer AL, Rosenwald A and Staudt LM (2002) Lymphoid malignancies: the dark side of B-cell differentiation. Nature Review Immunology 2: 920-933<\/p>\n

Shehata MF (2005) Rel\/Nuclear factor kappaB apoptosis pathways in human cervical cancer cells. Cancer Cell International 5: 10<\/p>\n

Shimamura T, Hsu TC, Colburn NH and Bejcek BE (2002) Activation of NF-kB is required for PDGF-B chain to transform NIH3T3 cells. Experimental Cell Research 274: 157-167<\/p>\n

Smith D, Shimamura T, Barbera S and Bejcek BE (2007) NF-kB controls growth of glioblastomas\/astrocytomas. Molecular and Cellular Biochemistry in press<\/p>\n

Soos J, Engelhardt JI, Siklos L, Hayas L and Majtenyi K (2004) The expression of PARP, NF-kB and parvalbumin is increased in Parkinson disease. Neuroreport 15 1715-1718<\/p>\n

Sovak MA, Bellas RE, Kim DW, Zanieski GJ, Rogers AE, Traish AM and Sonenshein GE (1997) Aberrant nuclear factor-kB\/Rel expression and the pathogenesis of breast cancer. Journal of Clinical Investigation 100: 2952-2960<\/p>\n

Stathopoulos Gt, Sherrill TP, Han W, Sadikot RT, Yull FE, Blackwell TS and Fingleton B (2008) Host nuclear factor-kB activation potentiates lung cancer metastasis. Molecular Cancer Research 6: 364-371<\/p>\n

Staudt LM (2000) The molecular and cellular origins of Hodgkin\u2019s disease. Journal of Experimental Medicine 191: 207-212<\/p>\n

Stoffel A, Chaurushiya M, Singh B and Levine AJ (2004) Activation of NF-kappaB and inhibition of p53-mediated apoptosis by API2\/mucosa-associated lymphoid tissue 1 fusions promote oncogenesis. Proceedings of the National Academy of Sciences USA 101: 9079-9084<\/p>\n

Sutter AP, Zeitz M and Scherubl H (2004) Recent results in understanding molecular pathways in the medical treatment of esophageal and gastric cancer. Onkologie 27: 17-21<\/p>\n

Tai DI, Tsai SL, Chang YH, Huang SN, Chen TC, Chang KS and Liaw YF (2000) Constitutive activation of nuclear factor kB in hepatocellular carcinoma. Cancer 89: 2274-2281<\/p>\n

Tang X, Liu D, Shishodia S, Ozburn N, Behrens C, Lee JJ, Hong WK, Aggarwal BB and Wistuba II (2006) Nuclear factor-kB (NF-kB) is frequently expressed in lung cancer and preneoplastic lesions. Cancer: 107: 2637-2646<\/p>\n

Tegeder I, Niederberger E, Schmidt R, Kunz S, Guhring H, Ritzeler O, Michaelis M and Geisslinger G (2004) Specific Inhibition of IkB kinase reduces hyperalgesia in inflammatory and neuropathic pain models in rats. Journal of Neuroscience 24: 1637-1645<\/p>\n

Tew GW, Lorimer EL, Berg TJ, Zhi H, Li R and Williams CL (2007) SmgGDS regulates cell proliferation, migration, and NF-kB transcriptional activity in non-small cell lung carcinoma. Journal of Biological Chemistry, in press<\/p>\n

Torabian S and Kashani-Sabet M (2005) Biomarkers for melanoma. Current Opinions in Oncology 17: 167-171<\/p>\n

Tichelaar JW, Zhang Y, LeRice JC, Lam S and Anderson MW (2004) Activation of the Akt\/Nuclear Factor-kB signaling axis in developing lung neoplasia. Chest 125: 153S<\/p>\n

Todaro M, Zerilli M, Triolo G, Iovino F, Patti M, Accardo-Palumbo A, Gaudio FD, Turco MC, Petrella A, Maria RD and Stassi G (2005) NF-kB protects Behcet’s disease T cells against CD95-induced apoptosis up-regulating antiapoptotic proteins. Arthritis and Rheumatism 52: 2179-2191<\/p>\n

Toledo-Pereyra LH, Toledo AH, Walsh J and Lopez-Neblina F (2004) Molecular signaling pathways in ischemia\/reperfusion. Experimental and Clincal Transplantation\u00a0 2: 174-177<\/p>\n

Trompouki E, Hatzivassillou E, Tsichritzis T, Farmer H, Ashworth A and Mosialos G (2003) CYLD is a deubiquitinating enzyme that negatively regulates NF-kB activation by TNFR family members. Nature 424: 793-796<\/p>\n

Ueda Y & Richmond A (2006) NF-kB activation in melanoma. Pigment Cell Research 19: 112-124<\/p>\n

Valen G, Yan ZQ and Hansson GK (2001) Nuclear factor kB and the heart. Journal of the American College of Cardiology 38: 307-314<\/p>\n

Van den Oord JJ, Sarasin A, Winnepenninckx V and Spatz A (2007) Expression profiling of melanoma cell lines: in search of a progression-related molecular signature. Future Oncology 3: 609-611<\/p>\n

Vilimas T, Mascarenhas J, Palomero T, Mandal M, Buonamici S, Meng F, Thompson B, Spaulding C, Macaroun S, Alegre ML, Kee BL, Ferrando A, Miele L and Aifantis I (2006) Targeting the NF-kB signaling pathway in Notch1-induced T-cell leukemia. Nature Medicine 13: 70-77<\/p>\n

Visconti R, Cerutti J, Battista S, Fedele M, Trapasso F, Zeki K, Miano MP, de Nigris F, Casalino L, Curcio F, Santoro M and Fusco A (1997) Expression of the neoplastic phenotype by human thyroid carcinoma cell lines requires NFkB p65 protein expression. Oncogene 15: 1987-1994<\/p>\n

Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary K and Chiao PJ (1999) The NF-kB RelA transcription factor is constiutively activated in human pancreatic adenocarcinoma cells. Clinical Cancer Research 5: 119-127<\/p>\n

Weber CK and Adler G (2001) From acinar cell damage to systemic inflammatory response: current concepts in pancreatitis. Pancreatology 1: 356-362<\/p>\n

Weichert W, Boehm M, Gekeler V, Bahra M, Langrehr J, Neuhaus P, Denkert C, Imre G, Weller C, Hofmann HP, Niesporek S, Jacob J, Dietel M, Scheidereit C and Kristiansen G (2007) High expression of RelA\/p65 is associated with activation of nuclear factor-kB-dependent signaling in pancreatic cancer and marks a patient population with poor prognosis. British Journal of Cancer 97: 523-530<\/p>\n

Whitehead IP, Lambert QT, Glaven JA, Abe K, Rossman KL, Mahon GM, Trzaskos JM, Kay R, Campbell SL and Der CJ (1999) Dependence of Dbl and Dbs transformation on MEK and NF-kB activation. Molecular and Cellular Biology 19: 7759-7770<\/p>\n

Widera D, Kaus A, Kaltschmidt C and Kaltschmidt B (2007) Neural stem cells, inflammation and NF-kB: basic principle of maintenance and repair or origin of brain tumours? Journal of Cellular and Molecular Medicine in press<\/p>\n

Wilson SH, Caplice NM, Simari RD, Holmes Jr DR, Carlson PJ and Lerman A (2000) Activated nuclear factor-kB is present in the coronary vasculature in experimental hypercholesterolemia. Atherosclerosis 148: 23-30<\/p>\n

Wratten ML, Brendolan A, Ronco C, La Greca G and Tetta C (2001) Should we target signal pathways instead of single mediators in the treatment of sepsis? Contributions to Nephrology 132: 400-414<\/p>\n

Wu L, Pu Z, Feng J, Li G, Zheng Z and Shen W (2007) The ubiquitin-proteasome pathway and enhanced activity of NF-kB in gastric carcinoma. Journal of Surgical Oncology in press<\/p>\n

Xiong HQ (2004) Molecular targeting therapy for pancreatic cancer. Cancer Chemotherapy and Pharmacology 54: S69-S77<\/p>\n

Xu R, Xu G, Shi J and Wen W (2007) A correlative study of NF-kB activity and cytokines expression in human chronic nasal sinusitis. Journal of Laryngology and Otology 121: 644-649<\/p>\n

Xu Z, Chen S, Li X, Luo G, Li L and Le W (2006) Neuroprotective effects of (-)-epigallocatechin-3-gallate in a transgenic mouse model of amyotrophic lateral sclerosis. Neurochemistry Research 31: 1263-1269<\/p>\n

Yamamoto Y and Gaynor RB (2001) Role of the NF-kB pathway in the pathogenesis of human disease states. Current Molecular Medicine 1: 287-296<\/p>\n

Yang CW, Wu MS and Pan MJ (2001) Leptospirosis renal disease. Nephrology Dialysis Transplantation 16 Suppl 5: 73-77<\/p>\n

Yang J and Richmond A (2001) Constitutive IkB kinase activity correlates with nuclear factor-kB activation in human melanoma cells. Cancer Research 61: 4901-4909<\/p>\n

Yang Q, Zhao GQ, Li Q and Liu XP (2006) Expression of nuclear factor-kB in traumatic cataract. Chinese Journal of Traumatology 9: 86-90<\/p>\n

Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M and Shoelson SE (2001) Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of IKKb. Science 293: 1673-1677<\/p>\n

Zea AH, Culotta KS, Ali J, Mason C, Park HJ, Zabaleta J, Garcia LF and Ochoa AC (2006) Decreased expression of CD3 zeta and nuclear transcription factor kB in patients with pulmonary tuberculosis: potential mechanisms and reversibility with treatment. Journal of Infectious Diseases 194: 1385-1393<\/p>\n

Zhang D, Jin X, Wang F, Wang S, Deng C, Gao Z and Guo C (2007) Combined prognostic value of both RelA and IkB-a expression in human non-small cell lung cancer. Annals of Surgical Oncology, in press<\/p>\n

Zhang Z, Ma J, Li N, Sun N and Wang C (2006) Expression of nuclear factor-kappaB and its clinical significance in nonsmall-cell lung cancer. Annals of Thoracic Surgery 82 243-248<\/p>\n

Zhang Z and Rigas B (2006) NF-kB, inflammation and pancreatic carcinogenesis: NF-kB as a chemoprevention target. International Journal of Oncology 29: 185-192<\/p>\n

Zheng L, Sinniah R and Hsu SI-H (2005) In situ glomerular expression of activated NF-kB in human lupus nephritis and other non-proliferative proteinuric glomerulopathy. Virchows Archiv 448: 172-183<\/p>\n

Zheng L, Sinniah R and Hsu SI-H (2006) Renal cell apoptosis and proliferation may be linked to nuclear factor-kappaB activation and expression of inducible nitric oxide synthase in patients with lupus nephritis.\u00a0 Human Pathology 37: 637-647<\/p>\n

Zheng L, Sinniah R and Hsu SI (2008) Pathogenic role of NF-kB activation in tubulointerstitial inflammatory lesions in human lupus nephritis. Journal of Histochemistry and Cytochemistry, in press<\/p>\n

Zhou X, Li F, Kong L, Tomita H, Li C and Cao W (2005) Involvement of inflammation, degradation and apoptosis in a mouse model of glaucoma. Journal of Biological Chemistry 280: 31240-31248<\/p>\n

Zhu J, Hu G and Sun Y (2004) Expression and significance of nuclear factor kB in laryngeal carcinoma [Article in Chinese]. Lin Chuang Er Bi Yan Hou Ke Za Zhi 18: 745-6, 766<\/p>\n

Zima TO and Kalousova M (2005) Oxidative stress and signal transduction pathwyas in alcoholic liver disease. Alcoholism, Clinical and Experimental Research 29 (Supplement): 110S-115S<\/p>\n","protected":false},"excerpt":{"rendered":"

NF-kB DISEASES On this page are listed several diseases in which activation of NF-kB has been implicated.\u00a0 For general reviews on the role of NF-kB in disease, see Aradhya & Nelson (2001), Kumar et al (2004), Yamamoto & Gaynor (2002) or Baldwin (2001).\u00a0 For specific diseases see the listed references, which can be found either […]<\/p>\n","protected":false},"author":4258,"featured_media":0,"parent":334,"menu_order":4,"comment_status":"closed","ping_status":"open","template":"","meta":[],"_links":{"self":[{"href":"https:\/\/www.bu.edu\/nf-kb\/wp-json\/wp\/v2\/pages\/183"}],"collection":[{"href":"https:\/\/www.bu.edu\/nf-kb\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.bu.edu\/nf-kb\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.bu.edu\/nf-kb\/wp-json\/wp\/v2\/users\/4258"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bu.edu\/nf-kb\/wp-json\/wp\/v2\/comments?post=183"}],"version-history":[{"count":9,"href":"https:\/\/www.bu.edu\/nf-kb\/wp-json\/wp\/v2\/pages\/183\/revisions"}],"predecessor-version":[{"id":486,"href":"https:\/\/www.bu.edu\/nf-kb\/wp-json\/wp\/v2\/pages\/183\/revisions\/486"}],"up":[{"embeddable":true,"href":"https:\/\/www.bu.edu\/nf-kb\/wp-json\/wp\/v2\/pages\/334"}],"wp:attachment":[{"href":"https:\/\/www.bu.edu\/nf-kb\/wp-json\/wp\/v2\/media?parent=183"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}